✦ LIBER ✦

Vaccination against lethalClostridium difficileenterocolitis with a nontoxic recombinant peptide of toxin A

✍ Scribed by David M. Lyerly; John L. Johnson; Steven M. Frey; Tracy D. Wilkins

Publisher: Springer
Year: 1990
Tongue: English
Weight: 438 KB
Volume: 21
Category: Article
ISSN: 0343-8651
DOI: 10.1007/bf02090096

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Production of a recombinant cholera toxi

Production of a recombinant cholera toxin B subunit-insulin B chain peptide hybrid protein by Brevibacillus choshinensis expression system as a nasal vaccine against autoimmune diabetes

✍ Yoshikazu Yuki; Chisato Hara-Yakoyama; Abigail A.E. Guadiz; Shigezo Udaka; Hiros 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

Synergistic action of human recombinant

Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice

✍ Nanne Bloksma; Frans M. A. Hofhuis 📂 Article 📅 1987 🏛 Springer-Verlag 🌐 English ⚖ 758 KB

Evaluation of chemical degradation of a

Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry

✍ Tia Estey; Christina Vessely; Theodore W. Randolph; Ian Henderson; LaToya Jones 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB

Vaccines utilizing recombinant protein antigens typically require an adjuvant to enhance immune response in the recipients. However, the consequences of antigen binding to adjuvant on both the short-and long-term stability of the protein remain poorly defined. In our companion paper (Vessely et al.,

Phase I/II vaccination study of recombin

Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll

✍ S. Schwander; M. Dietrich; M. Opravil; R. Lüthy; D. G. Hanson; J. Schindler; A. 📂 Article 📅 1994 🏛 Springer-Verlag 🌐 English ⚖ 695 KB